Sagimet Biosciences Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $14.0 million compared to $10.4 million in the prior year period. The company held $257.6 million in cash and marketable securities as of June 30, 2026, which management expects will fund operations through 2028, including data readout from its Phase 3 denifanstat trial. Sagimet announced plans to initiate a registrational Phase 3 clinical trial for denifanstat in moderate to severe acne patients in the United States during the second half of 2026. Additionally, the company confirmed that its first-in-human Phase 1 trial for the FASN inhibitor TVB-3567 is ongoing and aims to begin a Phase 2 acne trial before the end of 2026. Sagimet Biosciences Inc. operates in the clinical-stage biopharmaceutical industry, developing novel fatty acid synthase inhibitors for metabolic and dermatological diseases.
